Medical management of langerhans cell histiocytosis from diagnosis to treatment

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 9, 2012, Pages 1309-1322

  Donadieu, Jean ^a   Chalard, François ^a   Jeziorski, Eric ^b  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

Author keywords

Clinical workup; Diagnosis; Follow up; Guidelines; Langerhans cell histiocytosis; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CHLORMETHINE; CLADRIBINE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; IMATINIB; IMMUNOGLOBULIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RETINOIC ACID; RETINOID; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE; VINCRISTINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEURYSMAL BONE CYST; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATYPICAL MYCOBACTERIOSIS; BILE DUCT TUMOR; BONE RADIOGRAPHY; CELLULITIS; CHICKENPOX; CHILDHOOD LEUKEMIA; CHOLANGITIS; CHOLESTEATOMA; CHRONIC OSTEOMYELITIS; CHRONIC OTITIS MEDIA; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; DEGENERATIVE DISEASE; DIABETES INSIPIDUS; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DYSGERMINOMA; ECZEMA; ELECTRON MICROSCOPY; ENTERITIS; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; EWING SARCOMA; FEVER; FIBROUS DYSPLASIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOCHROMATOSIS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEPATITIS; HERPES SIMPLEX; HISTIOCYTOSIS; HISTIOCYTOSIS X; HUMAN; JUVENILE XANTHOGRANULOMA; LEIOMYOSARCOMA; LUNG FUNCTION; LYMPHOMA; MASTOCYTOSIS; MASTOIDITIS; METABOLIC DISORDER; MONOTHERAPY; MYELOMA; NEUROBLASTOMA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; OSTEOPOROSIS; OSTEOSARCOMA; PARASITOSIS; PLEURODESIS; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE; REVIEW; REYE SYNDROME; RHABDOMYOSARCOMA; SALVAGE THERAPY; SARCOIDOSIS; SCABIES; SEBORRHEIC DERMATITIS; SKIN BIOPSY; SOFT TISSUE SARCOMA; SOFT TISSUE TUMOR; STEROID THERAPY; SURGICAL DRAINAGE; TERATOMA; TREATMENT INDICATION; ULTRASOUND;

DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; PREDICTIVE VALUE OF TESTS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84861368087     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.688028     Document Type: Review

References (67)

1. Gadner H, Heitger A, Grois N, et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol 1994;23:72-80
2. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001;138:728-34
3. Gadner H, Grois N, Potschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2007;111:2556-62
4. Minkov M, Grois N, Heitger A, et al. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr 2000;212:139-44
5. The French Langerhans' Cell Histiocytosis Study Group. A multicentre retrospective survey of Langerhans' cell histiocytosis : 348 cases observed between 1983 and 1993. Arch Dis Child 1996;75:17-24
6. Chikwava K, Jaffe R. Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatr Dev Pathol 2004;7:607-14
7. Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am J Surg Pathol 2008;32:615-19
8. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. IARC press; Lyon: 2008
9. Valladeau J, Ravel O, zutter-Dambuyant C, et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000;12:71-81
10. Jaffe R. The diagnostic histopathology of Langerhans cell histiocytosis. In: Weitzman S, Egeler M, editors. Histiocytic Disorders of Children and Adults. Cambridge University Press; Cambridge: 2005. p. 14-39
11. Howarth DM, Mullan BP, Wiseman GA, et al. Bone scintigraphy evaluated in diagnosing and staging Langerhans' cell histiocytosis and related disorders. J Nucl Med 1996;37:1456-60
12. Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer 2009;52:97-101
13. Goo HW, Yang DH, Ra YS, et al. Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol 2006;36:1019-31
14. Vassallo R, Ryu JH, Colby TV, et al. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 2000;342:1969-78
15. Martin-Duverneuil N, Idbaih A, Hoang-Xuan K, et al. MRI features of neurodegenerative Langerhans cell histiocytosis. Eur Radiol 2006;16:2074-82
16. Prayer D, Grois N, Prosch H, et al. MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis. AJNR Am J Neuroradiol 2004;25:880-91
17. Minkov M, Grois N, Heitger A, et al. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol 2002;39:581-5
18. Tazi A, Soler P, Hance AJ. Adult pulmonary Langerhans' cell histiocytosis. Thorax 2000;55:405-16
19. Braier J, Latella A, Balancini B, et al. Outcome in children with pulmonary Langerhans cell Histiocytosis. Pediatr Blood Cancer 2004;43:765-9
20. Ronceray L, Potschger U, Janka G, et al. Pulmonary involvement in pediatric-onset multisystem langerhans cell histiocytosis: effect on course and outcome. J Pediatr Jan 26 2012. [Epub ahead of print]
21. Grois N, Potschger U, Prosch H, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer 2006;46:228-33
22. Barthez MA, Araujo E, Donadieu J. Langerhans cell histiocytosis and the central nervous system in childhood: evolution and prognostic factors. Results of a collaborative study. J Child Neurol 2000;15:150-6
23. Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr 2010;156:873-81.881
24. Donadieu J, Rolon MA, Thomas C, et al. Endocrine involvement in pediatric-onset Langerhans' cell histiocytosis: a population-based study. J Pediatr 2004;144:344-50
25. Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer 2004;42:438-44
26. Bernstrand C, Sandstedt B, Ahstrom L, Henter JI. Long-term follow-up of Langerhans cell histiocytosis: 39 years' experience at a single centre. Acta Paediatr 2005;94:1073-84
27. Sartoris DJ, Parker BR. Histiocytosis X: rate and pattern of resolution of osseous lesions. Radiology 1984;152:679-84
28. Womer RB, Raney RB Jr, D'Angio GJ. Healing rates of treated and untreated bone lesions in histiocytosis X. Pediatrics 1985;76:286-8
29. Donadieu J, Piguet C, Bernard F, et al. A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatr Blood Cancer 2004;43:770-6
30. Canuet M, Kessler R, Jeung MY, et al. Correlation between high-resolution computed tomography findings and lung function in pulmonary Langerhans cell histiocytosis. Respiration 2007;74:640-6
31. Tazi A, Marc K, Dominique S, et al. Serial CT and lung function testing in pulmonary Langerhans cell histiocytosis. Eur Respir J 2012;In press
32. Nanduri VR, Pritchard J, Levitt G, Glaser AW. Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis. Eur J Cancer 2006;42:2563-9
33. Trouillas P, Takayanagi T, Hallett M, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997;145:205-11
34. Allen CE, Flores R, Rauch R, et al. Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside. Pediatr Blood Cancer 2009;54:416-23
35. Idbaih A, Donadieu J, Barthez MA, et al. Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: a prospective pilot study. Pediatr Blood Cancer 2004;43:55-8
36. Imashuku S, Shioda Y, Kobayashi R, et al. Neurodegenerative central nervous system disease as late sequelae of Langerhans cell histiocytosis. Report from the Japan LCH Study Group. Haematologica 2008;93:615-18
37. Egeler RM, Thompson RC Jr, Voute PA, Nesbit ME Jr. Intralesional infiltration of corticosteroids in localized Langerhans' cell histiocytosis. J Pediatr Orthop 1992;12:811-14
38. Sheehan MP, Atherton DJ, Broadbent V, Pritchard J. Topical nitrogen mustard: an effective treatment for cutaneous Langerhans cell histiocytosis. J Pediatr 1991;119:317-21
39. Hadfield PJ, Birchall MA, Albert DM. Otitis externa in Langerhans' cell histiocytosis-the successful use of topical nitrogen mustard. Int J Pediatr Otorhinolaryngol 1994;30:143-9
40. Roger G, Dupre M, Leboulanger N, et al. Cholesteatoma secondary to temporal bone involvement by Langerhans cell histiocytosis: a complication amenable to curative surgery. Otol Neurotol 2009;30:190-3
41. Morimoto A, Ikushima S, Kinugawa N, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer 2006;107:613-19
42. Arico M, Girschikofsky M, Genereau T, et al. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer 2003;39:2341-8
43. Weitzman S, Braier J, Donadieu J, et al. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer 2009;53:1271-6
44. Bernard F, Thomas C, Bertrand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005;41:2682-9
45. Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005;36:215-25
46. Munn SE, Olliver L, Broadbent V, Pritchard J. Use of indomethacin in Langerhans cell histiocytosis. Med Pediatr Oncol 1999;32:247-9
47. Ng Wing TS, Martin-Duverneuil N, Idbaih A, et al. Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nation wide retrospective study. Orphanet J Rare Dis 2011;6:83
48. Gavhed D, Laurencikas E, Akefeldt SO, Henter JI. Fifteen years of treatment with intravenous immunoglobulin in central nervous system Langerhans cell histiocytosis. Acta Paediatr 2011;100:e36-9
49. Chohan G, Barnett Y, Gibson J, et al. Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab. J Neurol Neurosurg Psychiatry 2012;83:573-5
50. Broadbent V, Pritchard J. Diabetes insipidus associated with Langerhans cell histiocytosis: is it reversible? Med Pediatr Oncol 1997;28:289-93
51. Ottaviano F, Finlay JL. Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol 2003;25:575-7
52. Donadieu J, Rolon MA, Pion I, et al. Incidence of growth hormone deficiency in pediatric-onset Langerhans cellhistiocytosis: efficacy and safety of growth hormone treatment. J Clin Endocrinol Metab 2004;89:604-9
53. Minkov M, Steiner M, Potschger U, et al. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J Pediatr 2008;153:700-5.705
54. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:1919-23
55. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
56. Begum S, Rosenbaum E, Henrique R, et al. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol 2004;17:1359-63
57. Ball DW. Selectively targeting mutant BRAF in thyroid cancer. J Clin Endocrinol Metab 2010;95:60-1
58. Poynter JN, Elder JT, Fullen DR, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006;16:267-73
59. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
60. Available from www.eurohistionet 2012
61. Available from: www histiocytesociety org 2012
62. Talanin NY, Smith SS, Shelley ED, Moores WB. Cutaneous histiocytosis with Langerhans cell features induced by scabies: a case report. Pediatr Dermatol 1994;11:327-30
63. Geissmann F, Nosjean MC, Dezutter C, et al. Accumulation of immature Langerhans cells in human lymph nodes draining chronically inflamed skin. J Exp Med 2002;196:417-30
64. Perret-Court A, Coulibaly B, Ranque S, et al. Intradural dirofilariasis mimicking a Langerhans cell histiocytosis tumor. Pediatr Blood Cancer 2009;53:485-7
65. Maghnie M, Cosi G, Genovese E, et al. Central diabetes insipidus in children and young adults. N Engl J Med 2000;343:998-1007
66. Marchand I, Barkaoui MA, Garel C, et al. Central diabetes insipidus as the inaugural manifestation of Langerhans cell histiocytosis: natural history and medical evaluation of 26 children and adolescents. J Clin Endocrinol Metab 2011;96:E1352-60
67. Favara BE, Jaffe R, Egeler RM. Macrophage activation and hemophagocytic syndrome in langerhans cell histiocytosis: report of 30 cases. Pediatr Dev Pathol 2002;5:130-40